title: Dopamine disorder in duodenal ulceration.
abstract: Cysteamine-induced duodenal ulcers in rats were prevented by the dopamine agonists bromocriptine, lergotrile, and apomorphine, whereas both the severity of duodenal ulcers and the mortality among cysteamine-treated rats were raised by the dopamine receptor antagonist, haloperiodol. Bromocriptine and lergotrile greatly reduced gastric-acid output in cysteamine-treated rats. A review of the literature shows a high incidence of duodenal ulcers in patients with Parkinson's disease (associated with dopamine deficiency) and a low occurrence in schizophrenics (associated with dopamine excess and/or hyperactivity). Thus, changes in peripheral and/or central dopamine concentrations and/or receptor activity may have a role in the pathogenesis of duodenal ulceration.
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents; D001058:Apomorphine / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D003543:Cysteamine / Q000009:adverse effects / Q000037:antagonists & inhibitors; D004298:Dopamine / Q000172:deficiency*; D004357:Drug Synergism; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000209:etiology*; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D005750:Gastric Juice / Q000187:drug effects; D006220:Haloperidol / Q000009:adverse effects; D010868:Pimozide / Q000009:adverse effects; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects
chemical_list: D000897:Anti-Ulcer Agents; D004873:Ergolines; D011954:Receptors, Dopamine; D010868:Pimozide; D001971:Bromocriptine; D003543:Cysteamine; D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine